Alzamend Neuro is trading 6% up at $1.65, primarily supported by broad biotech-sector strength as XBI gains 2.06% during the August 25, 2026 session.
- No new company-specific announcement clearly explains the intraday rise.
- The most recent major filing disclosed a potential resale of 98,388,305 shares tied to convertible preferred stock, creating dilution overhang rather than a bullish catalyst.
- Broader market gains added support; confidence is medium because company-specific coverage is limited.